Semi artificial pancreas (AP) from Medtronic was FDA approved in 2016. The quest for full automated insulin pump continues. Current study evaluated the adaptive artificial pancreas technology in 30 adults with type 1 diabetes over a 12 week period.
By the end of the study, adaptive AP lowered A1c down to 6.7% from 7.0%. Day-time and night-time hypoglycemia also improved significantly. Software adaptations were manually overwritten 10% of the time.
Overall these are great advances toward user-independent artificial-intelligence pancreas. There will be more to come on the subject.